Vireo Growth Inc.

$85m committed across 1 active facility. VREOF

Pharmaceutical Preparations

Recent changes

  1. Aug 13, 2026Vireo Growth Inc. signs $85m CREDIT AGREEMENT, matures Aug 2031SEC ↗
Tested springingHeadroom not yet measured1.10x

Springing: Tested as of the last day of the Measurement Period most recently ended before, and each Measurement Period during, a Fixed Charge Trigger Period.

Permit the Consolidated Fixed Charge Coverage Ratio, determined on a Pro Forma Basis as of (i) the last day of the Measurement Period most recently ended before the commencement of a Fixed Charge Trigger Period and (ii) the last day of each Measurement Period thereafter ending during any Fixed Charge Trigger Period to be less than 1.10 to 1.00 for such Measurement Period.
Read the filing on sec.gov ↗

Download CSV · Download JSON

CREDIT AGREEMENT

Signed Aug 7, 2026

Committed
$85m
Matures
Aug 2031
TrancheSizeMaturesMargin
Revolving credit facility$85mAug 2031175–200 bps

Priced over Term SOFR, floor 0 bps (Revolving credit facility).

LevelConditionMarginUnused fee
Level I>50%175 bpsn/a
Level II< 50%200 bpsn/a

§1.01

Lenders: BMO Capital Markets

No amendments on file yet.

Report an error